BGM vs Bon Natural Life
BGM and BON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGM and BON compare
BGM scores higher on the StockData Score (9 against 0 for Bon Natural Life), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGM | BON |
|---|---|---|
| Size and price | ||
| Share price | $7.88 | $1.10 |
| Change, 1 year | −97.2% | −42.4% |
| Change, 5 years | −98.4% | −99.9% |
| Beta (5Y) | 0.27 | 0.94 |
| Employees | 206 | 96 |
| StockData Score | ||
| Total score | 9 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 51.1% | – |
| Revenue growth, 5Y average | −5.4% | – |
| Profitability | ||
| Gross margin | 16.6% | – |
| Operating margin | −33.2% | – |
| Net margin | −52.6% | – |
| FCF margin | −10.4% | – |
| Return on equity | −9.2% | – |
| Return on invested capital | −4.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.24 | – |
| Piotroski F-score | 4 | – |
| Ownership | ||
| Held by institutions | 0.00% | – |
| Held by insiders | 52.5% | 1.0% |
| Short interest, % of float | 0.00% | 0.17% |
Go deeper
- BGM stock overview
- BGM income statement
- BGM valuation and score
- BON stock overview
- BON income statement
- BON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.